Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
Cancer Immunology Research|April 12, 2017
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced MelanomaDaniel Y Wang, Zeynep Eroglu, Alpaslan Ozgun, et al.
Cancer|October 19, 2017
NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanomaRobert R McWilliams, Jacob B Allred, Jessica A Slostad, et al.
Melanoma Research|June 7, 2012
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanomaKevin B Kim, Victor Prieto, Richard W Joseph, et al.
European Urology Focus|July 21, 2017
Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy ResponseThai H Ho, Toni K Choueiri, Kai Wang, et al.
Plos One|July 17, 2015
A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, ArizonaThai H Ho, Rafael Nunez Nateras, Huihuang Yan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2017
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic MelanomaCaroline Robert, Antoni Ribas, Omid Hamid, et al.
Journal for Immunotherapy of Cancer|December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)Brian I Rini, Dena Battle, Robert A Figlin, et al.
BJU International|April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinomaSumanta K Pal, David F McDermott, Michael B Atkins, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaLisa Zimmer, Susmitha Apuri, Zeynep Eroglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapyRichard W Joseph, Vijay R Peddareddigari, Ping Liu, et al.
Pageof 9